Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Uveal Melanoma 1Lung Neoplasms 1Lung Diseases 1Colorectal Neoplasms 1Carcinoma 1Bronchial Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 18Pemetrexed 10Paclitaxel 6pembrolizumab 5Nivolumab 5Cisplatin 5Gemcitabine 4osimertinib 3entinostat 3camrelizumab 3atezolizumab 3Erlotinib Hydrochloride 3selpercatinib 2pralsetinib 2durvalumab 2apatinib 2Vinorelbine 2Surveys and Questionnaires 2One-Lung Ventilation 2Ipilimumab 2Drug Delivery Systems 2Docetaxel 2Bronchoscopy 2Bevacizumab 2130-nm albumin-bound paclitaxel 2zipalertinib 1zimberelimab 1toripalimab 1taletrectinib 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Diseases × Toll-Like Receptor 1 × Thoracic × Clear all
NCT04614103 2026-04-15

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Iovance Biotherapeutics, Inc.

Phase 2 Recruiting
170 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡